ADAR1 Capital Management LLC Sells 1,693,398 Shares of Zura Bio Limited (NASDAQ:ZURA)

ADAR1 Capital Management LLC lessened its holdings in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 44.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,077,251 shares of the company's stock after selling 1,693,398 shares during the period. Zura Bio accounts for 1.0% of ADAR1 Capital Management LLC's holdings, making the stock its 22nd biggest position. ADAR1 Capital Management LLC owned about 3.18% of Zura Bio worth $5,193,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Aristides Capital LLC bought a new stake in shares of Zura Bio during the fourth quarter worth approximately $74,000. Wells Fargo & Company MN boosted its stake in Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after purchasing an additional 9,379 shares during the period. Geode Capital Management LLC grew its holdings in Zura Bio by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock valued at $2,389,000 after buying an additional 42,801 shares in the last quarter. JPMorgan Chase & Co. increased its position in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after buying an additional 2,611,532 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of Zura Bio during the fourth quarter worth $28,000. 61.14% of the stock is owned by institutional investors.

Zura Bio Stock Up 8.0 %

Shares of ZURA traded up $0.09 during midday trading on Friday, hitting $1.21. The company's stock had a trading volume of 181,510 shares, compared to its average volume of 390,547. Zura Bio Limited has a one year low of $0.97 and a one year high of $6.35. The stock has a market capitalization of $82.73 million, a price-to-earnings ratio of -2.28 and a beta of 0.08. The company's fifty day simple moving average is $1.32 and its two-hundred day simple moving average is $2.50.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. On average, research analysts predict that Zura Bio Limited will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZURA. HC Wainwright reaffirmed a "buy" rating on shares of Zura Bio in a research report on Thursday, April 3rd. Guggenheim reiterated a "buy" rating and issued a $15.00 price target on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital lowered their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. Finally, Oppenheimer reiterated an "outperform" rating and set a $19.00 target price (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $14.67.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.